Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (48)
Claudia RUBINO, Fabiana BLUNDA, Francesca BODEGA, Francesco MELILLO, Anita RUSSI, Paolo MATTIELLO, Anna SALERNO, Michela CERA, Davide MARGONATO, Patrizio MAZZONE, Paolo DELLA BELLA, Alessandro CASTIGLIONI, Ottavio ALFIERI, Michele DE BONIS, Matteo MONTORFANO, Massimo FILIPPI, Moreno TRESOLDI, Alberto CAPPELLETTI, Alberto ZANGRILLO, Alberto MARGONATO & Cosmo GODINO. (2023) Safety and efficacy of direct oral anticoagulants (DOACs) in very elderly patients (≥85 years old) with non-valvular atrial fibrillation. Minerva Medica 114:2.
Crossref
Crossref
Thu Pham, Parth Patel, Daniel Mbusa, Alok Kapoor, Sybil Crawford, Hammad Sadiq, Sanjeev Rampam, Joann Wagner, Jerry H. Gurwitz & Kathleen M. Mazor. (2022) Impact of a pharmacist intervention on DOAC knowledge and satisfaction in ambulatory patients. Journal of Thrombosis and Thrombolysis 55:2, pages 346-354.
Crossref
Crossref
Hye‐Rim Kang, Wei‐Hsuan Lo‐Ciganic, Christina E. DeRemer, Eric A. Dietrich, Pei‐Lin Huang & Haesuk Park. (2022) Effectiveness and Safety of Extended Oral Anticoagulant Therapy in Patients with Venous Thromboembolism: A Retrospective Cohort Study. Clinical Pharmacology & Therapeutics 112:1, pages 133-145.
Crossref
Crossref
Christina E. DeRemer, Eric A. Dietrich, Hye‐Rim Kang, Pei‐Lin Huang, Wei‐Hsuan Lo‐Ciganic & Haesuk Park. (2022) Comparison of effectiveness and safety for low versus full dose of apixaban during extended phase oral anticoagulation in patients with venous thromboembolism. Journal of Internal Medicine 291:6, pages 877-885.
Crossref
Crossref
Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix, Mar Genís Gironès, David Gasche, Aurélie Millier, Jean Tardu, Mondher Toumi & Jean-Baptiste Briere. (2022) Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain. PLOS ONE 17:4, pages e0266658.
Crossref
Crossref
Niti M. Patel, Britney A. Stottlemyer, Matthew P. Gray, Richard D. Boyce & Sandra L. Kane-Gill. (2021) A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Cardiovascular Drugs and Therapy 36:2, pages 309-322.
Crossref
Crossref
Viviane Khalil. (2022) Evaluation of oral anticoagulant prescribing patterns and associated hospital acquired complications – a single centre Australian study. Journal of Pharmacy Practice and Research 52:2, pages 117-123.
Crossref
Crossref
Souad Moudallel, Pieter Cornu, Alain Dupont & Stephane Steurbaut. (2021) Determinants for under‐ and overdosing of direct oral anticoagulants and physicians' implementation of clinical pharmacists' recommendations. British Journal of Clinical Pharmacology 88:2, pages 753-763.
Crossref
Crossref
Ghazi I Arishi, Mohammed S Sheik & Abdulaziz Alhossan. (2022) Appropriateness of Prescribing Rivaroxaban at King Khalid University Hospital Riyadh. Cureus.
Crossref
Crossref
Sarah Landry, Shannon Ip, Jennifer Shiu & Tammy J. Bungard. (2021) Practice patterns surrounding referral to a specialty venous thromboembolism (VTE) clinic: a retrospective review. Journal of Thrombosis and Thrombolysis 53:1, pages 176-181.
Crossref
Crossref
Hazera Haque, Abdulrhman Alrowily, Zahraa Jalal, Bijal Tailor, Vicky Efue, Asif Sarwar & Vibhu Paudyal. (2021) Direct oral anticoagulant-related medication incidents and pharmacists’ interventions in hospital in-patients: evaluation using reason’s accident causation theory. International Journal of Clinical Pharmacy 43:6, pages 1693-1704.
Crossref
Crossref
Bruria Hirsh Raccah, Yevgeni Erlichman, Arthur Pollak, Ilan Matok & Mordechai Muszkat. (2021) Prescribing Errors With Direct Oral Anticoagulants and Their Impact on the Risk of Bleeding in Patients With Atrial Fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics 26:6, pages 601-610.
Crossref
Crossref
Pablo Domínguez-Erquicia, Sergio Raposeiras-Roubín, Emad Abbu-Assi, María Cespón-Fernández, David Alonso-Rodríguez, Santiago Jesús Camacho-Freire, Naiara Cubelos-Fernández, Álvaro López-Masjuán Ríos, María Melendo-Viu & Andrés Iñíguez-Romo. (2021) Predictors of Inappropriate Dosing of Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation. Journal of the American Medical Directors Association 22:11, pages 2395-2397.
Crossref
Crossref
B. A. Tatarsky & N. V. Kazyonnova. (2021) Safety and interaction of direct oral anticoagulants with antiarrhythmic drugs. Russian Journal of Cardiology 26:7, pages 4482.
Crossref
Crossref
Viviane Khalil. (2021) Redesign of computerized decision support system to improve Non Vitamin K oral anticoagulant prescribing—A pre and post qualitative and quantitative study. International Journal of Medical Informatics 152, pages 104511.
Crossref
Crossref
Sydney W Strickland, Surabhi Palkimas, Mary Acker & Lindsay A L Bazydlo. (2021) A Novel Laboratory Assay to Monitor Unfractionated Heparin Dosing in Patients Taking Apixaban Prior to Hospital Admission. The Journal of Applied Laboratory Medicine 6:2, pages 378-386.
Crossref
Crossref
Walter Ageno, Alfredo Farjat, Sylvia Haas, Jeffrey I. Weitz, Samuel Z. Goldhaber, Alexander G.G. Turpie, Shinya Goto, Pantep Angchaisuksiri, Joern Dalsgaard Nielsen, Gloria Kayani, Sebastian Schellong, Henri Bounameaux, Lorenzo G. Mantovani, Paolo Prandoni & Ajay K. Kakkar. (2021) Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE. Research and Practice in Thrombosis and Haemostasis 5:2, pages 326-341.
Crossref
Crossref
Peter L. Gross & Noel C. Chan. (2021) Thromboembolism in Older Adults. Frontiers in Medicine 7.
Crossref
Crossref
Mohammed Somaili, Nivethika Jeyakumar, Eric McArthur, Christine Ribic, Manish M. Sood, Ziv Harel & Amber O. Molnar. (2020) Incidence of Direct Oral Anticoagulant Prescriptions in Kidney Transplant Recipients in Ontario, Canada. Transplantation Proceedings 52:10, pages 3144-3152.
Crossref
Crossref
Sabina Sankhi, Nirmal Raj Marasine, Parbati Thapa & Nim Bahadur Dangi. (2020) Anticoagulant Utilization and Cost Analysis among Cardiology Inpatients in a Tertiary Care Teaching Hospital of Western Nepal. Advances in Pharmacological and Pharmaceutical Sciences 2020, pages 1-6.
Crossref
Crossref
Cosmo Godino, Francesca Bodega, Francesco Melillo, Francesca Rubino, Antonio L.M. Parlati, Alberto Cappelletti, Patrizio Mazzone, Paolo Mattiello, Paolo Della Bella, Alessandro Castiglioni, Ottavio Alfieri, Michele De Bonis, Matteo Montorfano, Moreno Tresoldi, Massimo Filippi, Alberto Zangrillo, Anna Salerno, Michela Cera & Alberto Margonato. (2020) Inappropriate dose of nonvitamin-K antagonist oral anticoagulants: prevalence and impact on clinical outcome in patients with nonvalvular atrial fibrillation. Journal of Cardiovascular Medicine 21:10, pages 751-758.
Crossref
Crossref
Aubrey E. Jones, Jordan B. King, Kibum Kim & Daniel M. Witt. (2020) The role of clinical pharmacy anticoagulation services in direct oral anticoagulant monitoring. Journal of Thrombosis and Thrombolysis 50:3, pages 739-745.
Crossref
Crossref
Zhu Xian Zhang, Ewoudt M. W. Garde, Maaike Söhne, Ankie M. Harmsze & Marcel P. H. Broek. (2020) Quality of clinical direct oral anticoagulant prescribing and identification of risk factors for inappropriate prescriptions. British Journal of Clinical Pharmacology 86:8, pages 1567-1574.
Crossref
Crossref
Nijole Bernaitis, Michelle Bowden & Adam La Caze. (2020) A clinical audit of oral anticoagulant therapy in aged care residents with atrial fibrillation. International Journal of Clinical Pharmacy 42:2, pages 474-481.
Crossref
Crossref
Barbara S. Wiggins, Dave L. Dixon, Ron R. Neyens, Robert L. PageIIII & Ty J. Gluckman. (2020) Select Drug-Drug Interactions With Direct Oral Anticoagulants. Journal of the American College of Cardiology 75:11, pages 1341-1350.
Crossref
Crossref
John A. Saunders, Whitney L. Gustafson, Sara R. Vazquez, Aubrey E. Jones & Daniel M. Witt. (2019) Real-world assessment of off-label direct oral anticoagulant dosing for venous thromboembolism. Journal of Thrombosis and Thrombolysis 48:3, pages 506-510.
Crossref
Crossref
Stefania Antoniazzi, Ilaria Ardoino, Marco Proietti, Valter Monzani, Pier Mannuccio Mannucci, Alessandro Nobili & Carlotta Franchi. (2019) Appropriateness of prescription of oral anticoagulant therapy in acutely hospitalized older people with atrial fibrillation. Secondary analysis of the SIM‐AF cluster randomized clinical trial. British Journal of Clinical Pharmacology 85:9, pages 2134-2142.
Crossref
Crossref
Daniela Valencia, Patrick Spoutz, Jaclyn Stoppi, Jeffery L. KibertIIII, Arthur Allen, David Parra & Augustus Hough. (2019) Impact of a Direct Oral Anticoagulant Population Management Tool on Anticoagulation Therapy Monitoring in Clinical Practice. Annals of Pharmacotherapy 53:8, pages 806-811.
Crossref
Crossref
Carlotta Franchi, Stefania Antoniazzi, Ilaria Ardoino, Marco Proietti, Maura Marcucci, Paola Santalucia, Valter Monzani, Pier Mannuccio Mannucci & Alessandro Nobili. (2019) Simulation-Based Education for Physicians to Increase Oral Anticoagulants in Hospitalized Elderly Patients with Atrial Fibrillation. The American Journal of Medicine 132:8, pages e634-e647.
Crossref
Crossref
Nasser Alali, Mahmoud Hassan Mahmoud, Mousa Ayesh Alharbi & Sami Nimer Ghazal. (2019) Appropriateness of dabigatran dosing in patients with nonvalvular atrial fibrillation (NVAF): A retrospective study conducted in a tertiary care university hospital in the eastern province of Saudi Arabia. Journal of the Saudi Heart Association 31:3, pages 130-134.
Crossref
Crossref
Nicklas Vinter, Marie Linder, Morten Andersen, Alma B. Pedersen, Morten Madsen, Stephen E. Schachterle, Quazi Ataher, Jingping Mo, Søren Paaske Johnsen & Vera Ehrenstein. (2019) Classification and characteristics of on-label and off-label apixaban use in Denmark and Sweden. Pharmacoepidemiology and Drug Safety 28:6, pages 867-878.
Crossref
Crossref
V. V Tarasov, Vladimir N. Chubarev, E. S Zykova, A. S Belosludtsev, E. G Mokshanova, S. S Sologova, S. A Lebedeva, E. M Grigorevskikh, T. A Zatsepilova, N. G Preferanskaya, N. Z Musina & D. I Sologova. (2019) DIRECT ORAL ANTICOAGULANTS: A COMPARISON OF EFFICACY AND SAFETY, ERRORS IN THEIR APPLICATION, AND THE USAGE OF REVERSAL AGENTS. Medical Journal of the Russian Federation 25:2, pages 127-134.
Crossref
Crossref
Carlos Escobar, Julio Martí-Almor, Alejandro Pérez Cabeza & M. José Martínez-Zapata. (2019) Anticoagulantes orales directos frente a antagonistas de la vitamina K en pacientes con fibrilación auricular de la práctica clínica: revisión sistemática y metanálisis. Revista Española de Cardiología 72:4, pages 305-316.
Crossref
Crossref
Carlos Escobar, Julio Martí-Almor, Alejandro Pérez Cabeza & M. José Martínez-Zapata. (2019) Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis. Revista Española de Cardiología (English Edition) 72:4, pages 305-316.
Crossref
Crossref
María Cerdá, Juan J Cerezo-Manchado, Erik Johansson, Fernanda Martínez, Mariana Fernández, Ana Varela, Saray Rodríguez, Francesc Bosch & Amparo Santamaría. (2019) Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population. Journal of Comparative Effectiveness Research 8:3, pages 165-178.
Crossref
Crossref
Drakeria Barr & Quovadis J. Epps. (2018) Direct oral anticoagulants: a review of common medication errors. Journal of Thrombosis and Thrombolysis 47:1, pages 146-154.
Crossref
Crossref
Mohamed Shokr, Abdelrahman Ahmed, Hossam Abubakar, Ziad Sayedahmad, Ahmed Rashed, Luis Afonso & Shaun Cardozo. (2019) Use of direct oral anticoagulants in the treatment of left ventricular thrombi: A tertiary center experience and review of the literature. Clinical Case Reports 7:1, pages 135-142.
Crossref
Crossref
Anne-Laure Sennesael, Anne-Sophie Larock, Jonathan Douxfils, Laure Elens, Gabriel Stillemans, Martin Wiesen, Max Taubert, Jean-Michel Dogné, Anne Spinewine & François Mullier. (2018) Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. Thrombosis Journal 16:1.
Crossref
Crossref
Souad Moudallel, Stephane Steurbaut, Pieter Cornu & Alain Dupont. (2018) Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing. Frontiers in Pharmacology 9.
Crossref
Crossref
Ahmed Yacoob Mayet, Ahmed Ibrahim Alsaqer, Abdullah Musa Alhammad & Hussain Abdulrahman Al-Omar. (2018) Rivaroxaban prescribing in a Saudi tertiary care teaching hospital. Saudi Pharmaceutical Journal 26:6, pages 775-779.
Crossref
Crossref
Joseph P. Fava, Katelyn M. Starr, David Ratz & Jennifer L. Clemente. (2018) Dosing challenges with direct oral anticoagulants in the elderly: a retrospective analysis. Therapeutic Advances in Drug Safety 9:8, pages 405-414.
Crossref
Crossref
Anne-Laure Sennesael, Anne-Sophie Larock, Bérangère Devalet, Valérie Mathieux, Franck Verschuren, Xavier Muschart, Olivia Dalleur, Jean-Michel Dogné & Anne Spinewine. (2018) Preventability of serious thromboembolic and bleeding events related to the use of oral anticoagulants: a prospective study. British Journal of Clinical Pharmacology 84:7, pages 1544-1556.
Crossref
Crossref
Yesenia Pimentel Quezada, Juan Luis Bonilla Palomas, Antonio Luis Gámez López, Mirian Moreno Conde, María Cristina López Ibáñez & Ángel Gallego de la Sacristana López-Serrano. (2018) Has the clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban changed in the last 5 years of use?. Future Cardiology 14:3s, pages 47-53.
Crossref
Crossref
David Brun Guinda, Óscar Callen García, Jorge Ondiviela Pérez, María Gracia Aznarez, Pilar Artero Bello, Elena Rivero Fernandez, Adolfo Marquina Barcos & Maite Villarroel Salcedo. (2018) Clinical profile, management and outcomes in a cohort of elderly and highly comorbid patients with nonvalvular atrial fibrillation treated with rivaroxaban in routine practice. Future Cardiology 14:3s, pages 39-45.
Crossref
Crossref
Juan José Cerezo-Manchado, Begoña Navarro-Almenzar, Ginés Elvira-Ruiz, Faustino García-Candel, Pedro José Flores-Blanco, Cesar Caro-Martínez, Sergio Manzano-Fernández, Natalia García-Iniesta, Javier Sánchez-García, Valentín Cabañas-Perianes & José María Moraleda-Jiménez. (2018) Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke. Future Cardiology 14:3s, pages 31-37.
Crossref
Crossref
Sara Muñiz Lobato, Carlos Tarrazo Tarrazo, Elena González Fernández & Marlén Morán Alcalá. (2018) Clinical profile, adequacy of dosage and thromboembolic and bleeding outcomes in patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital of Asturias, Spain. Future Cardiology 14:3s, pages 17-24.
Crossref
Crossref
Alejandro Isidoro Pérez Cabeza, José Antonio González Correa, Pedro Antonio Chinchurreta Capote, Rafael Bravo Marqués, Francisco Ruiz Mateas, Gabriel Rosas Cervantes, Fidel Mesa Prado, Sergio López Tejero & Almudena Valle Alberca. (2018) Drug persistence and outcomes in a cohort of patients with nonvalvular atrial fibrillation treated with rivaroxaban after 2 years of follow-up in clinical practice. Future Cardiology 14:3s, pages 9-16.
Crossref
Crossref
Edelmira Martí, Alejandra Segado, Irene Pastor-Galán, Paula Amat, Maria José Remigia, Carlos Solano & Blanca Navarro. (2018) Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain. Future Cardiology 14:3s, pages 3-8.
Crossref
Crossref